ArticleJournal of the American Academy of Child and Adolescent Psychiatry2022
Editorial: Beyond Red Light, Green Light: Examining the Role of Pharmacogenomics in Evidence-Based Care in Child and Adolescent Psychiatry.
Article in Journal of the American Academy of Child and Adolescent Psychiatry, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Pharmacogenetic-Guided Antidepressant Prescribing in Adolescents (PGx-GAP): Study Protocol for a Randomized Controlled Trial.Journal of personalized medicine · 2026Article
- Exploring perceived barriers and attitudes in young adults towards antidepressant pharmacotherapy, including the implementation of pharmacogenetic testing to optimize prescription practices.Frontiers in pharmacology · 2024Article
- Utility of pharmacogenetic testing to optimise antidepressant pharmacotherapy in youth: a narrative literature review.Frontiers in pharmacology · 2023Review
- Pediatric Psychopharmacology for Depressive and Anxiety Disorders.Focus (American Psychiatric Publishing) · 2022Review
Corrections and comments
- Comment on
Authors and funding
5 authors.
Funding
Abstract
The role of pharmacogenetics in guiding psychopharmacologic treatment for children and adolescents remains elusive for many clinicians. In the absence of a solid and comprehensive evidence base, sufficient training, education, and consensus guidelines, commercial promotion of pharmacogenetic testing panels has the potential to become the main source of information for providers. Commonly, these tests include multigene panels and group medications into color-coded bins. These panels include both pharmacokinetic (PK) and pharmacodynamic (PD) genes and, using combinatorial algorithms, direct clinicians to use medications "as directed" or caution that "moderate gene-drug interaction(s)" or "significant gene-drug interaction(s)" may exist. Many industry-sponsored studies in adults have concluded that that when clinicians select medications based on pharmacogenomic guidance, patients have better outcomes,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.